Memory Enhancement by A Genetic Increase in cAMP Signals

通过 cAMP 信号的遗传增强增强记忆

• 批准号: 7764779
• 负责人: DANIEL R STORM
• 金额: $ 32.19万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7764779
• 关键词: AMPA Receptors; Ablation; Address; Adenylate Cyclase; Alzheimer' s Disease; Animals; Antisense Oligonucleotides; Area; Binding; Brain; Brain-Derived Neurotrophic Factor; Breeding; CREB-binding protein; CREB1 gene; Ca(2+)-Calmodulin Dependent Protein Kinase; Calcium; Calcium-Sensing Receptors; Calmodulin; Calmodulin-Binding Proteins; Crossbreeding; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotides; Data; Defect; Drug Delivery Systems; Educational Status; Elements; Enzymes; Event; Exhibits; Extinction (Psychology); Fright; Genes; Genetic; Genetic Enhancement; Genetic Transcription; Grant; Hereditary Disease; Hippocampus (Brain); In Vitro; Kinetics; LacZ Genes; Learning; Long-Term Potentiation; Maps; Mediating; Memory; Mental Retardation; Mitogen-Activated Protein Kinases; Molecular; Mouse Strains; Mus; Mutation; N-Methyl-D-Aspartate Receptors; N-Methylaspartate; Neurons; Nuclear Translocation; Oligonucleotides; Pathway interactions; Patients; Phenotype; Phosphorylation; Phosphorylation Site; Phosphotransferases; Principal Investigator; Property; Prosencephalon; Proteins; Quality of life; Receptor Inhibition; Relative (related person); Reporter; Research Personnel; Rubinstein-Taybi Syndrome; Signal Transduction; Site; Slice; Specific qualifier value; Technology; Testing; Time; Training; Transgenic Mice; Transgenic Organisms; Wild Type Mouse; adenylyl cyclase 1; base; drug development; human CREBBP protein; human disease; improved; in vivo; inhibitor/antagonist; insight; interest; knockout gene; long term memory; mouse CREB binding protein; mouse model; mutant; neurotrophic factor; novel; object recognition; overexpression; phosphoric diester hydrolase; postsynaptic; programs; promoter; receptor coupling; research study; response

DESCRIPTION (provided by applicant): Several human diseases including Alzheimer's and Rubinstein-Taybi syndrome are characterized by memory defects. The development of drugs to enhance the memory of compromised patients could have a major impact on the quality of life for these patients and others with memory defects. Evidence from several labs indicates that memory in mice may be enhanced using inhibitors of cyclic nucleotide phosphodiesterases (PDEs) to increase cAMP in the brain. Another promising drug target site to increase cAMP specifically in the brain is AC1, a neurospecific adenylyl cyclase that it is stimulated by activity-dependent calcium increases. To test this idea genetically, we made mice overexpressing AC1 in the hippocampus using the Ipha-CaM Kinase II promoter. These transgenic mice (AC1+) show enhanced LTP and memory for novel objects as well as a reduced rate of contextual memory extinction. Preliminary data indicate that the gain in memory may be due to enhanced signaling through the MAPK pathway. These data suggest the interesting possibility that AC1 may be a pharmacological "window of opportunity" to enhance memory formation. The major objective of this grant is to determine why AC1+ mice have superior memory. We hypothesize that AC1+ mice show memory enhancement because of the unique regulatory properties of AC1 which include its calcium sensitivity and synergistic activation by Gs-coupled receptors and calcium. We hypothesize that AC1+ mice show superior memory for novel objects because of more robust training- induced CRE-mediated transcription. This may be due to training-induced amplification MAPK activity, MAPK nuclear translocation, or postsynaptic depolarizations. We also propose that genetic enhancement of AC1 activity in the brain may overcome memory defects associated with Rubinstein-Taybi syndrome, a genetic disease due to a truncated form of the CREB binding protein (CBP).

描述（由申请人提供）：包括阿尔茨海默氏症和鲁宾斯坦-泰比综合征在内的几种人类疾病的特征在于记忆缺陷。开发增强受损患者记忆力的药物可能会对这些患者和其他记忆缺陷患者的生活质量产生重大影响。来自几个实验室的证据表明，使用环核苷酸磷酸二酯酶（PDE）抑制剂增加大脑中的cAMP可以增强小鼠的记忆力。另一个有前途的药物靶点，以增加cAMP在大脑中的特异性是AC 1，神经特异性腺苷酸环化酶，它是由活动依赖性钙增加刺激。为了从遗传学上验证这一想法，我们使用Ipha-CaM激酶II启动子在海马体中过度表达AC 1。这些转基因小鼠（AC 1+）表现出增强的LTP和对新物体的记忆，以及降低的上下文记忆消退率。初步数据表明，记忆力的增加可能是由于通过MAPK途径增强的信号传导。这些数据表明了一种有趣的可能性，即AC 1可能是增强记忆形成的药理学“机会之窗”。这项资助的主要目的是确定为什么AC 1+小鼠具有上级记忆力。我们推测，AC 1+小鼠表现出记忆增强，因为AC 1的独特的调节特性，其中包括其钙敏感性和协同激活的GS-偶联受体和钙。我们假设，AC 1+小鼠表现出对新物体的上级记忆，因为更强大的训练诱导的CRE介导的转录。这可能是由于训练诱导的MAPK活性扩增，MAPK核转位，或突触后去极化。我们还提出，大脑中AC 1活性的遗传增强可能会克服与Rubinstein-Taybi综合征相关的记忆缺陷，Rubinstein-Taybi综合征是一种由于CREB结合蛋白（CBP）截短形式引起的遗传性疾病。